Browsing Tag
Type 1 diabetes
17 posts
Sanofi (SNY) wins a pivotal Tzield label expansion into recently diagnosed stage 3 type 1 diabetes
Sanofi (SNY) wins FDA accelerated approval for Tzield in recently diagnosed stage 3 type 1 diabetes, expanding its market beyond screening. Full analysis here.
Why NCEL-101’s FDA pathway could influence the future of stem-cell-derived islet therapies
Why NewcelX Ltd.’s FDA pre-IND process for NCEL-101 could shape the future of regenerative diabetes medicine. Read the full analysis.
ImmuPharma at 4p is a P140 licensing bet: What IMM retail investors should know
ImmuPharma targets a P140 licensing deal in 2026 with cash to H2 2028. Here is what IMM retail investors need to weigh before chasing the small-cap biotech.
Why the EMA review of PolTREG-T1D could influence autoimmune cell therapy development
PolTREG-T1D moves toward European Medicines Agency review. Discover how this TREG cell therapy could reshape treatment for autoimmune diseases.
FDA green light fast-tracks Diamyd Medical’s type 1 diabetes verdict by nine months
Diamyd Medical accelerates its Phase 3 type 1 diabetes trial after FDA alignment. Find out what the earlier data readout means for approval prospects.
NLS Pharmaceutics and Kadimastem merger gains BIRD Foundation boost for breakthrough Type 1 diabetes therapy
Discover how NLS Pharmaceutics and Kadimastem’s merger, backed by renewed BIRD Foundation funding, positions NewCelX to challenge global leaders in diabetes cell therapy.
vTv Therapeutics begins Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes patients
vTv Therapeutics has launched its Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes. Find out what this means for patients and investors today.
UK approves first-ever immunotherapy for type 1 diabetes — can teplizumab really delay onset by three years?
MHRA approves teplizumab, the UK’s first immunotherapy for type 1 diabetes, delaying onset by three years. See how it could reshape care pathways.
Stem cell-based diabetes therapies at ADA 2025 show promise in eliminating insulin use for type 1 patients
VX-880 and immune-shielded stem cell islets show strong promise in clinical trials at ADA 2025, offering new possibilities in type 1 diabetes treatment.
Smart insulin system improves glucose control for pregnant women with type 1 diabetes, according to ADA 2025 clinical trial findings
Smart insulin system shows improved glucose control in pregnancy with type 1 diabetes, per ADA 2025 trial; regulatory expansion expected. Read full details.